Objectives: In this prospective, double-blind, placebo-controlled study we observed the influence of treatment with candesartan 8mg on restenosis rates after stent implantation into the femoral artery ...

The presence of migraine is a significant risk factor for the development of subsequent peripheral artery occlusive disease, according to results of a retrospective cohort study published in the ...

THE treatment of the patient with peripheral arterial insufficiency is increasingly successful. During the course of the disease, however, the physician is frequently called upon to resolve problems ...

HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic ...

Peripheral artery disease in primary care Early diagnosis of this common manifestation of atherosclerosis is critical. Risk factors include smoking, diabetes, hypertension, and obesity. Approximately ...

Coronary heart disease (CHD) is one of the most common comorbidities in patients with heart failure (HF) with mildly reduced ...

In the treatment of larger narrowed blood vessels, drug-coated balloon catheters have been shown to deliver lasting and effective outcomes. Their minimally invasive nature makes them a viable ...

Male and female patients, aged between 45 and 75 years, were eligible for enrolment. All subjects recruited for this study had a diagnosis of mild hypertension (resting systolic [RR sys] BP >140mm Hg ...

Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia HELSINKI, 12 March 2026 - Aplagon, a ...